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Abstract The electronic healthcare databases are start-
ing to become more readily available and are thought to
have excellent potential for generating adverse drug re-
action signals. The Health Improvement Network (THIN)
database is an electronic healthcare database contain-
ing medical information on over 11 million patients that
has excellent potential for detecting ADRs. In this pa-
per we apply four existing electronic healthcare data-
base signal detecting algorithms (MUTARA, HUNT,
Temporal Pattern Discovery and modified ROR) on the
THIN database for a selection of drugs from six chosen
drug families. This is the first comparison of ADR sig-
nalling algorithms that includes MUTARA and HUNT
and enabled us to set a benchmark for the adverse drug
reaction signalling ability of the THIN database. The
drugs were selectively chosen to enable a comparison
with previous work and for variety. It was found that
no algorithm was generally superior and the algorithms’
natural thresholds act at variable stringencies. Further-
more, none of the algorithms perform well at detecting
rare ADRs.
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1 Introduction
It is an unavoidable consequence that prescription drugs
frequently cause unwanted side effects due to the un-
predictability of how a drug will interact with all the
body functions [23]. When a negative side effect has
been associated with a drug, it is referred to as an ad-
verse drug reaction (ADR). Clinical trials are used as
a means to identify common ADRs, but are not suit-
able at detecting all the possible ADRs. The reason
clinical trials cannot find all the ADRs is due to the
trials being limited by time constraints, sample popu-
lation size, sample population bias and unrealistic con-
ditions [16]. For example, outside of a clinical trial it
is common practice for a patient to be taking multi-
ple prescription drugs but not all co-prescriptions can
be monitored during clinical trials. It is also common
for certain subpopulations such as children or pregnant
women to be underrepresented in trials due to ethical
reasons. As a consequence, post marketing surveillance
is constantly required to identify any previously undis-
covered ADR throughout the time a drug is actively
prescribed. Pharmacovigilance signal detection is the
process of identifying potential adverse reactions to a
drug that were previously unknown. Once a tentative
signal is generated, it is further evaluated to confirm
causation between the drug and adverse drug reaction,
if causation is shown, we refer to the signal as a true
signal, if causation is not shown, it is a false signal.
The majority of the traditional posts marketing sur-
veillance techniques make use of spontaneous reporting
system (SRS) databases, databases containing volun-
tary records of suspected drug and ADR pairs. The SRS
algorithms generate tentative ADR signals by finding
medical events that occur disproportionally more of-
ten after a specific drug compared to any drug in the
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database. The existing SRS algorithms include calculat-
ing measures frequently used in epidemiology such as
the reporting odds ratio [17] and proportional report-
ing ratio [9], a Bayesian approach [3] and an Empiri-
cal Bayes approach [8]. Due to the voluntary nature of
these databases information is often missing, incorrect
or duplicated [1]. It is also believed that some ADRs
may not be detectable by mining SRS databases due
to under-reporting [2], for example people may not be
bothered to report less severe side effects or may not
notice a very rare ADR. The existing algorithms ap-
plied to SRS databases have previously been described
as filters rather than definitive ADR detectors as the
tentative signals they generate still require further in-
vestigation to determine if they are true or false.
Recently a new type of medical database, the Elec-
tronic Healthcare Database (EHD), has started to at-
tract attention for scientific research and is expected to
become a fundamental component in future pharma-
covigilance [25]. It is common for this type of database
to contain a wealth of information such as complete
medical and drug prescription histories for a patient.
These databases offer a different perspective for detect-
ing ADRs than the SRS databases and current research
includes developing methods to mine EHDs or integrat-
ing EHDs and other healthcare databases together and
mining the combination [6] [4].
There has been a recent focus on developing al-
gorithms that can mine EHDs and a variety of algo-
rithms exist. A range of different methodologies have
been incorporated into signalling ADRs including case
control approaches [18], cohort approaches [20], modi-
fying older algorithms developed for SRS databases [7]
[28], developing sequential pattern mining based algo-
rithms aiming to find dependencies between drugs and
medical events by using a control group [11] [12], inves-
tigating temporal changes [15] or by calculating the log
likelihood over time [5]. One previous study applied and
compared a range of ADR signalling algorithms includ-
ing the SRS adapted disproportionality algorithms and
the Temporal Pattern Discovery (TPD) algorithm to
multiple EHDs [19]. They showed that the algorithms
investigated tended to return many false positive as-
sociations and that there was no clear optimal algo-
rithm, as the most suitable algorithm depends on the
desired trade off between the sensitivity and specificity.
Another study concluded that there were little differ-
ence between the signalling ability of the SRS adapted
disproportionality algorithms and a selection of cohort
and case control algorithms [21]. To date there has been
no comparison that includes the ADR signalling algo-
rithms known as Mining Unexpected Temporal Asso-
ciation Rules given the Antecedent (MUTARA) [11]
and Highlighting UTARs Negating TARs (HUNT) [12].
Both MUTARA and HUNT offer a unique perspective
for signalling ADRs for a specific drug of interest as
they are case control methods that incorporate a pa-
tient level filter. It is of interest to investigate how MU-
TARA and HUNT compare with the SRS adapted dis-
proportionality algorithms and the TPD algorithm as
these have been extensively investigated.
An EHD known as The Health Improvement Net-
work (THIN) is a UK database that contains time stamped
medical data on over 11 million patients and has excel-
lent potential for ADR signal detection. Recent work
has investigated the suitability of ADR signalling us-
ing the THIN database in it’s raw form compared to
a mapped form that enables it to be integrated with
other EHDs [27]. The study showed that many THIN
records were unable to be mapped but this did not ap-
pear to limit the signalling ability of the mapped THIN
database. In this paper, we applied a selection of ADR
signalling algorithms to the raw THIN database. This
enabled a benchmark to be determined that can be used
to aid the development of future ADR signalling algo-
rithms that are specific to the THIN database and can
utilise all the information contained within. This is im-
portant as we do not know all the possible ADRs for
any drug so there is no ‘golden standard’ to compare
ADRs signalling algorithms against. Furthermore, this
comparison enables us to determine the rare ADR sig-
nalling potential of each algorithm investigated as this
has not been previously studied. This is important as
algorithms mining the THIN database may be more
likely to signal rare ADRs (occurring in less than 1 in
1000 patients) compared to algorithms mining the SRS
databases due to the THIN database not relying on
voluntary reporting. Although rare ADRs do not occur
often, if they are severe (such as liver failure or death),
it is important to identify them and algorithms capa-
ble of signalling rare but severe ADRs would greatly
improve current healthcare.
In this paper we compare four existing algorithms
(HUNT, MUTARA, TPD and modified ROR) by ap-
plying them to the THIN database (www.thin-uk.com)
consisting of general practice records for patients regis-
tered at participating practices within the UK. In previ-
ous comparisons applied to other EHDs the algorithm’s
general ability of ranking ADR as well as it’s ability
of signalling ADRs at the natural threshold have been
investigated. For consistency, these measures are also
determined in this study on the THIN database.
The modified ROR and the TPD algorithm both
have natural signalling thresholds (the value of the lower
confidence interval is greater than 1 or 0 respectively).
HUNT and MUTARA were developed to return a ranked
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list of potential ADRs but MUTARA has a natural
threshold for signalling ADRs when the unexpected-
leverage is greater than 0. Unfortunately, HUNT does
not have a natural threshold so in this paper, for the
natural threshold comparison, we implement a thresh-
old of signalling the top 10% of the ranked events.
The general ability of identifying ADRs, independent
of their natural signalling thresholds, can be observed
by using rank based measures such as the area under
the Receiver Operator Characteristic (ROC) and the
average precision. The rank based measures are calcu-
lated by considering the top n ranked events by each
algorithm to be the tentative signals generated by each
algorithm. Although technically a signal corresponds to
an unknown potential ADR, for evaluation purposes in
this paper we generate signals by considering that there
are no known ADRs (so signals corresponding to a drug
and adverse reaction are generated even if the drug is
currently known to cause the adverse reaction) and use
the known ADR knowledge to determine the number of
true signals by finding how many of the known ADRs
are signalled by each algorithm. So, we use the number
of known ADRs occurring in the top n ranked events
by each algorithm to calculate the number of true sig-
nals generated by each algorithm where n determines
the signalling threshold. The sensitivity and specificity
can then be evaluated.
The continuation of this paper is as follows, sec-
tion 2 gives a background on the existing algorithms
describing the databases they were previously applied
to and previous results. Section 3 contains information
about the THIN database, the drugs investigated and
the method applied in this paper to compare the algo-
rithms. Section 4 presents the results of the comparison
method and is followed by a discussion in section 5. This
paper finishes with the conclusion in section 6.
2 Algorithms
The EHDs do not contain direct links between drugs
and medical events that are potential ADRs but these
links can be inferred by using the temporal informa-
tion in the database and finding all the medical events
that occur within a set time period after the drug is pre-
scribed. In this paper we are investigating the ability to
detect immediately occurring ADRs so we consider all
medical events that occur within 30 days of the drug
prescription as possible drug and ADR pairs. Justifi-
cation for investigating the 30 day time period after
a drug prescription is that this is a trade off between
having a long enough time period that under-reporting
will be minimised (as patients have time to report any
side effects) while reducing the amount of noise caused
Table 1 Contingency table used in existing SRS methods.
Event j =Yes Event j =No
Drug i=Yes w00 w01
Drug i=No w10 w11
by a long time period. After finding all the medical
events that occur within 30 days of the drug prescrip-
tion, the pharmacovigilance algorithms developed for
EHDs then calculate a dependency measure between
the drug and each medical event and return a list of
all medical events that occurred within 30 days of the
prescription for any patient ranked by the dependency
measure. The medical event ranked 1 is the medical
event that appears to have the greatest dependency on
the drug of interest having been previously prescribed.
The existing EHD algorithms calculate the dependency
measure differently and the majority implement a fil-
ter. We described the existing algorithms and the de-
pendency measures used in the sections below.
2.1 SRS Algorithms
2.1.1 SRS Algorithms & Background
The SRS algorithms were originally developed for gen-
eral SRS databases where the actual rate that a drug
is prescribed and the rate that a medical event occurs
is unknown, as SRS databases only contain data on
the drug prescriptions that may have resulted in an
ADR. Consequently, the SRS algorithms estimate the
background rate that a medical event occurs by find-
ing out how often the medical event is reported with
any drug in the database. Medical events that are re-
ported disproportionally more often with the drug of
interest compared to all the other drugs in the data-
base are then ranked highly as suspected ADRs. These
algorithms make use of a contingency table, see Table
1, summarising the number of reports that contain (or
do not contain) the drug and event of interest.
One example of an SRS algorithm is the reporting
odds ratio (ROR),
ROR =
w00/w10
w01/w11
(1)
where a measure of how often the medical event occurs
after the drug being investigated relative to how often
it occurs after any other drug (w00w10 ) is divided by how
often any other medical event occurs after the drug be-
ing investigated relative to how often they occur after
any other drug (w01w11 ).
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2.1.2 SRS algorithms Previous Results
Existing work by Zorych et al. applied the ‘modified
SRS algorithms’ to a simulated EHD database and a
real EHD database [28]. They first transformed the
EHD databases into an SRS style database contain-
ing reports of potential drug and ADR pairs by using
temporal relations, in a similar way as described at the
beginning of this section, see Fig. 1. After transform-
ing the EHD data into SRS data they then applied the
existing SRS disproportionality algorithms.
2.1.3 Implementation of the modified SRS algorithms
in this study
In this paper we use the ‘Spontaneous reporting system’
style transformation [28], where SRS style reports con-
sisting of a patient, drug prescription and possible ADR
are inferred from the EHD by discovering all the medi-
cal events that occur within 30 days of a drug prescrip-
tion. Fig. 1 illustrates an example of the transformation.
After the THIN database is transformed, as described
in Fig. 1, the ROR is applied. The left bound of the 90%
confidence interval of the ROR (ROR05) is calculated
for every event that occurs in at least three reports for
the drug of interest (w00 ≥ 3) and the medical events
are ranked based on the ROR05, see Eq. 2 [17] [28].
We chose to use the left bound of the 90% confidence
interval of the ROR as previous work showed that the
ROR05 was better at ranking medical events in terms
of how likely they are to be ADRs than the ROR [28].
So the measure of dependency used to rank the medical
events when applying the modified SRS algorithms to
the THIN database is the chosen SRS algorithm value
(in this case the ROR05) calculated on the SRS style
transformed database.
ROR05 = exp(ln(
w00/w10
w01/w11
)
− 1.645 ∗
√
1
w00
+
1
w01
+
1
w10
+
1
w11
)
(2)
2.2 MUTARA/HUNT
2.2.1 MUTARA/HUNT Background
The algorithms Mining Unexpected Temporary Asso-
ciation Rules given the Antecedent (MUTARA) [11]
and Highlighting UTARs, Negating TARs (HUNT) [12]
were developed to be implemented on the Queensland
Linked Data Set (QLDS) comprising of the Common-
wealth Medicare Benefits Scheme (MBS), Pharmaceu-
tical Benefits Scheme (PBS) and Queensland Hospi-
tal morbidity data. The QLDS contained hospital data
from the 1 July 1995 to 30 June 1999 and MBS/PBS
records from 1 January 1995 to 31 December 1999.
Medical events from the hospital data were recorded
by the International Statistical Classification of Dis-
eases and Related Health Problems (ICD) 9 system and
there were a total of 2020 different diagnoses. The drug
prescriptions were coded with the World Health Or-
ganization (WHO) Anatomical Therapeutic Chemical
(ATC) system [24] and the database contained a to-
tal of 758 distinct drug codes. The QLDS did not have
complete records for each patient and only contained
hospital records.
2.2.2 MUTARA/HUNT algorithms
Both MUTARA and HUNT make use of a dependency
measure known as the leverage that is frequently used
when mining sequential patterns. In the context of this
paper the leverage calculates the temporal dependency
of medical event C on drug A by finding the number of
patients that have drug A followed by medical event C
within a time period of T days (denoted A
T→ C) minus
the number of patients you would expected to have the
medical event after the drug if the drug A and medical
event C occurred independently of each other.
The algorithms apply a case control approach where
patients prescribed the drug are referred to as users
and patients that have never been prescribed the drug
are referred to as non-users. The non-users are used
to estimate the background rate that a medical event
occurs. When implementing the algorithms the values
Te, Tc, Tr, Tb ∈ N are input.
The algorithms first restrict their attention to sub-
sequences of the user and non-user sequences. For each
user sequence, the Th constrained subsequence of inter-
est is the subsequence of length Th days starting from
the day the drug is first prescribed. The value of Th dif-
fers between users depending on if the user has a repeat
prescription within Te days after the first prescription.
If the user does not have a repeat prescription within Te
days of the first prescription then Th = Te, whereas if
the second prescription of the drug occurs s days after
the first prescription where s ≤ Te then Th = s + Te.
For each non-user, the Tc constrained subsequence of
interest is a subsequence of length Tc days that is ran-
domly chosen from the non-user’s sequence. See Fig 2
for an illustration of how the subsequences are chosen.
We define tot to be the number of users and non-
users. Using the constrained subsequences, the supp(A
T→
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Fig. 1 The line represents the THIN data for patient Pat1 with the arrow showing the direction of time and each circle is
a day, with red circles representing a prescription of a drug and green circles representing an occurrence of a medical event.
To transform this into SRS style data, the drugs are paired with all the medical events that occur within 30 days, so the
THIN data represented in this Figure is transformed into seven SRS reports for the Pat1. The SRS style reports consist of
four SRS data entries for drug A (Pat1-drug A -medical events 1,Pat1-drug A-medical event 2,Pat1-drug A- medical event 3
and Pat1-drug A-medical event 4) and three SRS data entries for Drug B (Pat1-Drug B-medical event 2, Pat1-Drug B-medical
event 3 and Pat1-drug B-medical event 4).
C) is defined as the number of user Th constrained sub-
sequences containing the medical event C divided by
tot, the supp(A
T→) is the number of users divided by
tot and supp(
T→ C) is the number of user Th constrained
subsequences that contain the medical event C divided
by tot plus the number of non-user Tc constrained sub-
sequences that contain the medical event C divided by
tot. The leverage is calculated as,
Leverage = supp(A
T→ C)− supp(A T→)× supp( T→ C)
(3)
In addition to calculating the standard leverage, a
new measure called unexpected-leverage is also calcu-
lated. The unexpected-leverage (unexlev) makes use of
a user’s history to filter repeated medical events from
the users’s Th constrained subsequence as these are
‘predictable’ and unlikely to be ADRs. This is done by
investigating a reference period of length Tr days start-
ing from Tb days prior to the first prescription within
the user’s sequence and filtering medical events from
the user’s Th subsequence if they occurred during the
Tr days in the period prior to the first prescription. An
example of determining if an item is ‘predictable’ can be
seen in Fig. 3 where three medical events C2,C3 and C4
all occur within the Th days after the prescription but
the medical event C2 also occurred within the Tr days
prior to the prescription so it is considered to be ‘pre-
dictable’ and is filtered, whereas the medical events C3
and C4 do not occur within the Tr days prior so they
are not filtered. Defining supp(A
T
↪→ C) as the num-
ber of users who’s Th constrained subsequence contains
medical event C but who do not have medical event
C within the Tr days prior to the first prescription di-
vided by tot and supp(
T
↪→ C) as the total of the num-
ber of users who’s Th constrained subsequence contains
medical event C but who do not have medical event C
within the Tr days prior to the first prescription plus
the number of non-user Tc constrained subsequences
that contain the medical event C all divided by tot, the
unexpected leverage is calculated as,
unexlev = supp(A
T
↪→ C)− supp(A T→).supp( T↪→ C) (4)
MUTARA was designed to calculate the unexpected-
leverages for a drug and set of specified medical events.
MUTARA then ranks the medical events in descending
order of the unexpected-leverage, so the dependency
measure used by MUTARA for signalling ADRs is the
unexpected-leverage value.
The authors state that MUTARA is prone to thera-
peutic failures so HUNT was developed as an improve-
ment [12]. HUNT returns medical events in descending
order of the ratio between the leverage rank and the
unexpected-leverage rank,
RankRatio =
event rank based on leverage
event rank based on unexpected-leverage
(5)
The medical events are ranked such that the medical
event with the highest leverage/unexpected-leverage is
ranked number 1 and the higher the rank, the lower
the rank number. The reason the rank ratio works is
because the medical events that are true ADRs will
generally only occur after the drug is taken and will
not be filtered from the Th constrained subsequences,
so the leverage and unexpected-leverage of ADRs will
be approximately the same. The medical events that are
linked to the cause of taking the drug will occasionally
occur before the prescription for some patients and be
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Fig. 2 Example of a user sequence and a non-user sequence with the time periods illustrated. The red vertical lines in the
user sequence corresponds to the point in time that the user is prescribed the drug being investigated, non red vertical lines
correspond to prescriptions of other drugs and the circles correspond to medical events, with different colours representing
different medical events.
Fig. 3 Example of determining if an event is ‘predictable’ or not within the sequence. If the event occurs in the hazard
period Th and reference Tr period it is ‘predictable’, if it occurs in the hazard period and not the reference period it is not
‘predictable’.
filtered from the Th constrained subsequences, result-
ing in the unexpected-leverage being lesser than the
leverage. Therefore, the rank number of ADRs based
on unexpected-leverage will be less than or equal to
the rank number based on leverage (as medical events
linked to the cause of taking the drug will have moved
down the rankings), so the rank ratio will be greater
than or equal to 1, whereas medical events linked to
the cause of the drug will have an unexpected-leverage
rank number greater than or equal to the leverage rank
number, so the rank ratio will be less than or equal to
1. It is clear that ADRs will have a higher RankRatio
than therapeutic failure medical events.
2.2.3 MUTARA/HUNT Previous Results
MUTARA was applied on the QLDS for older females
given alendronate and within the top ten events re-
turned by the algorithm was reflux esophagitis, a known
ADR. The top two events returned by MUTARA were
linked to osteoporosis, the cause of taking the drug and
the other events were not listed and assumed to be
unlikely to be adverse drug events. This suggests the
precision of the top ten events (P (10)) is 0.1 for the
algorithm applied to QLDS with a specific strata.
HUNT was applied on the QLDS for the drug al-
endronate and the stratum consisting of older females.
The results show HUNT returned three known ADRs
within the top ten events returned. This corresponds
to an P (10) = 0.3. When alendronate was investigated
for older males, one known ADR was returned, corre-
sponding to an P (10) = 0.1.
2.2.4 Implementation of MUTARA/HUNT in this
study
In this study the set of medical events input in MU-
TARA and HUNT is the collection of any medical event
that occurred within 30 days of a first prescription of
the drug being investigated for any patient. The rea-
son behind choosing 30 days is for consistency with
the other algorithms in this study, enabling a fairer
comparison. We did not implement any stratification
and the chosen study period was all the records from
1900−2010. The algorithms MUTARA60 and HUNT60
referred to in the continuation of this paper were MU-
TARA and HUNT implemented with Tc = Te = 30,
Tr = Tb = 60 and the algorithms MUTARA180 and
HUNT180 referred to in the continuation of this paper
were MUTARA and HUNT implemented with Tc =
Te = 30, Tr = Tb = 180. We chose not to have a gap
between the reference period and date of first prescrip-
tion of the drug (Tr = Tb) as preliminary tests indicated
this gave better results due to many indicator events
occurring a few days prior to prescription.
2.3 TPD Ratio
2.3.1 TPD Ratio Background
Noren et al. developed the Temporal Pattern Discovery
(TPD) algorithm based on a measure of disproportion-
ality [15]. This method is very similar to the dispropor-
tionality methods applied to SRS databases.
The database the TPD was developed for is the
UK IMS Disease Analyzer containing over two million
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patients and 120 million prescriptions. Similar to the
THIN database, the UK IMS Disease Analyzer extracts
data directly from general practitioners computers. The
OE ratio was implemented on patient records up to
31 December 2005. The database contained 3445 drugs
and 5753 medical events encoded by the ICD-10 [26].
2.3.2 TPD algorithms
The TPD algorithm compares the number of patients
that have the first prescription of drug x in thirteen
months followed by event y within a set time t relative
to the expected number of patients if drug x and event
y were independent. Letting ntxy denote the number of
patients that have drug x for the first time (in thirteen
months) and event y occurs within time period t, nt.y
denote the number of patients that are prescribed any
drug for the first time (in thirteen months) and have
event y within time period t. ntx. denote the number of
patients that have drug x for the first time (in thirteen
months) with an active follow up in time period t and
nt.. denote the number of patients that have any drug for
the first time (in thirteen months) with an active follow
up in time period t. The expected number of patients
that have drug x and then event y in a time period t is
then,
Etxy = n
t
x.
nt.y
nt..
(6)
If for a given drug, the event occurs more than ex-
pected, the ratio between the observed and expected
will be greater than one. By taking the log2 of the ra-
tio, a positive values suggests an interesting association
between a drug and event. Modifying the equation to
prevent the problem of rare events or drugs resulting in
a small expectation that can cause volatility, a statisti-
cal shrinkage method is applied.
IC = log2
ntxy + 1/2
Etxy + 1/2
(7)
The shrinkage adds a bias for the IC towards zero when
an event or drug is rare. The credibility intervals for
the IC are the logarithm of the solution to Eq. 8 with
q = 0.025 and q = 0.975.∫ µq
0
(Etxy + 1/2)
ntxy+1/2
Γ (ntxy + 1/2)
u(n
t
xy+1/2)−1e−(n
t
xy+1/2)du = q
(8)
The above can find possible drug and event associa-
tions of interest for a given t, however, the authors sug-
gest that general temporal patterns can be found by
comparing the IC of two different time periods. The
follow-up period of primary interest is denoted by u
and the control time period by v. This removes event
and drug relationships that just happen to occur more
in certain sub-populations. The difference between the
IC for both time periods is,
log2
nuxy
Euxy
− log2
nvxy
Evxy
(9)
re-arranging and adding a shrinkage term gives,
IC∆ = log2
nuxy + 1/2
Eu∗xy + 1/2
(10)
where
Eu∗xy =
nvxy
Evxy
.Euxy (11)
In previous work, Noren et al. set u and v such that
30 days after the prescription is contrasted with a time
period of 27 to 21 months prior to prescription, this
centers the v period around the same time of the year
that the u period occurs preventing seasonal bias. The
TPD calculates the IC∆ for each medical event that oc-
curs within a month of the drug being investigated for
any patient and returns the list of the medical events
in descending order of the IC∆ value. In addition to
calculating the IC∆, a filter is applied to remove med-
ical events with an IC on the day of prescription or
the month prior higher than the IC for the time period
investigated after the prescription.
2.3.3 TPD Previous Results
The algorithm was applied to the UK IMS Disease An-
alyzer database for the drug nifedipine and found seven
known ADRs within the top ten non administrative
events returned. This corresponds to an P (10) = 0.7.
2.3.4 Implementation of TPD in this study
In this study we implemented the TPD as described
in [15], with 30 days after the first prescription in 13
months contrasted with 27 to 21 months prior to pre-
scription, but investigated two different filters:
– We apply the TPD and filter medical events with an
IC value the month prior to prescription or an IC
value on the prescription day greater than the IC
value during the month after the prescription (TPD
1).
– We apply the TPD and filter medical events with
an IC value the month prior to prescription greater
than the IC value during the month after the pre-
scription (TPD 2).
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The justification for choosing two filters is due to
the possibility that ADRs can occur and be reported to
doctors on the same day as the prescription, so filter-
ing events with an IC value on the day of prescription
greater than the IC value during the month after the
prescription may prevent detection of some ADRs. We
can investigate this by implementing both filters and
comparing the results.
3 Materials & Methods
3.1 THIN Database
The THIN database contains medical records from par-
ticipating general practices within the UK. The data are
anonymously extracted directly from the general prac-
tice Vision clinical system [10]. THIN then implements
validation steps; these are added as extra fields within
the tables. The database contains patient information
including the year of birth, gender, date of registra-
tion and family history of each patient registered at the
practice since participation. Any illness, symptom, pro-
cedure, laboratory test, diagnosis or other relevant in-
formation that a doctor learns about a patient (referred
to as a medical event) is recorded along with the cor-
responding date. Information regarding any medication
prescribed as well as the date of the prescription and the
dosage are also included in the database. For this com-
parison a database containing records from 495 general
practices was used. This subset of the THIN database
contained approximately four million patients, over 358
million prescription entries and over 233 million medi-
cal event entries.
Each medical event is recorded in the database by a
reference code known as a Read code. The Read codes
used in the THIN database are an independent system
designed specifically for primary care but every ICD-9-
CM (International Classification of Diseases, Ninth Edi-
tion, Clinical Modification) code (or analogues) have a
corresponding Read code [22]. The UK general prac-
tice database has a hierarchal event Read code struc-
ture. The longer the Read code the greater the detail.
For example ‘H32..00’ may represent the event ‘Depres-
sion’ whereas ‘H321.00’ may represent ‘Depression due
to medication’. The last two elements of the Read code
represent events of the same type but described differ-
ently for example ‘G1...00’ and ‘G1...01’ may represent
‘had a chat with patient’ and ’had a chin wag with pa-
tient’ respectively. Only the first five elements of the
Read codes were used in this study and Read codes
corresponding to administrative events were ignored as
they did not offer any information about ADRs. There
were a total of 90 122 different five element Read codes
used in this study.
3.2 Preprocessing the THIN Database
Data miners applying algorithms to EHDs obtained
from general practice records need to be careful with
newly register patients. As patients can change gen-
eral practices at any age, when they register they may
have a history of events that a doctor needs to record.
The term ‘registration event dropping’ is used when his-
toric or previously diagnosed events of newly registered
patients are entered into the database. For example,
when a new patient first visits their doctor they may
inform the doctor of a previously diagnosed chronic ill-
ness such as ‘diabetes’. This medical event will then
be input into the database with a date corresponding
to the visit, rather than the actual date the patient
was diagnosed with diabetes. As the dates recored for
the ‘registration event drops’ are frequently incorrect,
including them in a research study will bias results.
Research suggests that ’registration event dropping’ is
significantly reduced after a patient is registered for a
year. To prevent ’registration event dropping’ biasing
the results in this study, the first 12 months of medical
history after registration are ignored for each patient as
justified in [14].
As patients can move to a different practice at any
time (or die), in this study we only include prescrip-
tions into the study where the corresponding patient is
still active for a minimum of 30 days after. This pre-
vents the bias due to ‘under-reporting’ of adverse drug
events that may occur if a patient no longer attends the
practice. The last date a patient is active is considered
to be the maximum date of any record for the patient
or the patient’s date of death.
3.3 Drugs
To investigate the robustness of each existing algorithm,
we applied the existing algorithms to a range of drugs.
To determine if certain algorithms perform optimally
under specific conditions, we chose to study multiple
drugs from the same drug families. The reason we chose
multiple drugs from the same family is that the drugs
would generally have similar indications and side ef-
fects, but may have different rates of prescription or be
used by different groups of patients, for example the
drug may be predominantly prescribed to the young
or to females . Therefore, by comparing the algorithm
performance between drugs of the same family we are
controlling for patient medical state while investigating
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the effect that the attributes (average age, male propor-
tion, total number of patients) of the group of patients
prescribed each drug have on the algorithm.
The drugs Ibuprofen, Ketoprofen, Fenoprofen and
Celecoxib used in this study are all from the same drug
family known as non-steroidal anti-inflammatory drugs
(NSAIDs). These drugs are typically prescribed for con-
tinuous pain associated with inflammation and have a
variety of common side effects including gastrointesti-
nal disturbances, hypersensitivity reactions and depres-
sion. Rarer side effects include congestive heart failure,
renal failure and hepatic failure. Elderly patients are
more prone to side effects associated with NSAIDs. In
this study the the drugs tended to be prescribed sightly
more to females with the male proportion ranging from
0.335 − 0.405 and to older patients, although Ibupro-
fen was prescribed to younger patients more than the
other NSAID drugs. The NSAID drug prescribed the
most was Ibuprofen with over a million first in 13 month
prescriptions, whereas Fenoprofen was only prescribed
1225 times for the first time in 13 months, see Table 2.
The quinolones are a class of drugs used to treat bac-
terial infections such as respiratory track infections and
urinary-track infections. Ciprofloxacin, levofloxacin, mox-
ifloxacin, nalidixic acid and norfloxacin are drugs from
the quinolone family that are investigated in this pa-
per. The quinolones have many side effects, including
tendon rupture. The average age of the patients pre-
scribed the quinolones for the first time in 13 months
was similar between all the drugs, around the late fifties.
The male proportion shows that females are prescribed
quinolones more than males, but this was more obvi-
ous for norfloxacin and nalidixic acid. Ciprofloxacin was
the most prescribed quinolone and moxifloxacin was
the least common, with only 1465 prescriptions. Table
3 shows the information on the drugs from the THIN
database.
Tricyclic antidepressant drugs are a family of drugs
used to treat depression and are known to cause, among
others, cardiovascular and central nervous system side
effects. The three drugs, doxepin, lofepramine and nor-
triptyline where selected in this paper. The tricyclic
antidepressants investigated are prescribed to patients
with similar ages and genders and tend to be prescribed
more often to older females. The main difference be-
tween the drugs is that doxepin is only prescribed to
6752 patients whereas the other two drugs are pre-
scribed to more than 10000 patients, see Table 4.
The drugs nifedipine, nicardipine, amlodipine, felodip-
ine and verapamil are all calcium channel blocker that
are used to treat high blood pressure and raynaud’s
phenomenon. It is common for the calcium channel
blockers to be prescribed with other drugs and apply-
ing the existing algorithms to detect side effects on the
calcium channel blockers will investigate the effect of
confounding due to multiple prescriptions. The drug
nifidipine was previously used to investigate the TPD
applied to the UK IMA Disease Analyzer, so investigat-
ing the calcium channel blockers will also give insight
into how robust the TPD is when applied to different
electronic healthcare databases. The calcium channel
blockers are generally prescribed for the first time in
13 months to patients around 65 years old. Amlodip-
ine and nicardipine are prescribed only slightly more
to females than males, whereas the other calcium chan-
nel blockers investigated are prescribed even more often
to females. Amlodipine and nifedipine have been pre-
scribed over 100000 times for the first time in 13 months
in the THIN database, but nicardipine has only been
prescribed 2796 times, see Table 5.
The sulphonylurea drug family includes tolbutamide,
glibenclamide, gliclazide, glimepiride and glipizide. They
are a class of antidiabetic drugs used for the manage-
ment of type 2 diabetes mellitus. The sulphonylureas
are prescribed for the first time in 13 months to older
patients will an average age around 65 years old and
all the sulphoylureas investigated except tolbutamide
are prescribed more often to males, with approximately
equal male proportions. Glipizide and tolbutamide are
the less frequently prescribed sulphonylurea drugs. The
general information about each of the sulphonylurea
drugs can be seen in Table 6.
The last drug family is the Penicillin drugs amoxi-
cillin, ampicillin, flucloxacillin, benzylpenicillin and phe-
noxymethlypenicillin. These drugs are used to treat bac-
terial infections. The number of times the drugs are
recorded as being prescribed in the THIN database
varies between 2000 to over two million. There is also
a divergence between the average age of the patients
prescribed each of the drugs, with the penicillins gener-
ally being prescribed to younger patients than many of
the other drugs families investigated in this paper. The
male proportion is fairly similar between the different
penicillin drugs, with females being prescribed the drug
more often than males, see Table 7.
3.4 Comparison Method
Before calculating the comparison measures we applied
our own filter that is specific to the THIN database
to remove medical events that are chronic (as chronic
medical events are not side effects), that correspond to
cancer (as it is unlikely that cancer will develop as a
side effect within 30 days of the drug first being pre-
scribed) or those that are not related to the patient’s
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Table 2 Information about the NSAID drugs investigated in this paper. Total is the number of times the drug is prescribed
for the first time in 13 months, age is the average age of the patients who are prescribed the drug for the first time in 13 months
and male proportion is the number of patients that are male divided by the total number of patients who are prescribed the
drug for the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
celecoxib 68036 62946 62100 63416 62.49 0.335
ibuprofen 1178163 1012555 858819 903415 45.56 0.405
ketoprofen 72946 65718 61710 63536 58.17 0.375
fenoprofen 1255 1008 975 1036 56.29 0.404
Table 3 Information about the Quinolone drugs investigated in this paper. Total is the number of times the drug is prescribed
for the first time in 13 months, age is the average age of the patients who are prescribed the drug for the first time in 13 months
and male proportion is the number of patients that are male divided by the total number of patients who are prescribed the
drug for the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
ciprofloxacin 280011 250158 227739 235420 55.64 0.440
levofloxacin 7662 7028 6775 6928 60.55 0.43
norfloxacin 14876 13224 12220 12625 56.83 0.262
moxifloxacin 1465 1347 1343 1371 62.09 0.419
nalidixic acid 4273 3646 3620 3787 55.63 0.127
Table 4 Information about the tricyclic drugs investigated in this paper. Total is the number of times the drug is prescribed
for the first time in 13 months, age is the average age of the patients who are prescribed the drug for the first time in 13 months
and male proportion is the number of patients that are male divided by the total number of patients who are prescribed the
drug for the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
doxepin 6752 6029 5908 6104 56.69 0.316
lofepramine 45532 38565 37642 39517 51.39 0.285
nortriptyline 11775 10519 10307 10650 54.43 0.286
Table 8 Table illustrating a TP, FP, FN and TN. Listed
event means the medical event is listed on the British Na-
tional Formulary as a known side effect and non-listed event
means it is not listed as a known side effect.
Listed event Non-listed event
Signalled True Positive (TP) False Positive (FP)
Not Signalled False Negative (FN) True Negative (TN)
health (such as administration events or occupation in-
formation). Without this filter the performance of each
algorithm was reduced.
3.4.1 Natural threshold based measures
The signalling ability of each algorithm using the natu-
ral threshold was investigated by calculating the sensi-
tivity and specificity at their natural thresholds (0 for
MUTARA/TPD and 1 for ROR) using the values de-
scribed in Table 8.
Sensitivity =
TP
TP + FN
(12)
Specificity =
TN
TN + FP
(13)
3.4.2 Rank based measures
Each data mining algorithm, as described in section 2,
is applied to the THIN database and a ranked list of
medical events is returned for each drug investigated.
The non filtered medical events are ranked in descend-
ing order of the association between the drug of interest
and medical event, so medical events the algorithm has
deemed more likely to be ADR are ranked higher, an
example of this can be seen in Table 9. Each algorithm
is then analysed by investigating how well it has ranked
each of the known ADRs that have occurred in the re-
turned ranked list. The known ADRs are those that
are listed in the British National Formulary (BNF) [13]
for the specific drug, or medical events described as
‘adverse reaction to drug x’ or containing information
about the continuation of the drug prescription.
Given a ranked set of events, we calculate the Truth
measure y(i) for the i
th ranked event, by letting y(i) = 1
if the event is a known ADR and y(i) = 0 otherwise,
as shown in Table 9. Table 9 shows an example of a
returned list containing five events ranked by an al-
gorithm and the corresponding y values. Using the y
values we can then use the measures described below
to compare the different algorithms.
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Table 5 Information about the calcium channel blocker drugs investigated in this paper. Total is the number of times the
drug is prescribed for the first time in 13 months, age is the average age of the patients who are prescribed the drug for the
first time in 13 months and male proportion is the number of patients that are male divided by the total number of patients
who are prescribed the drug for the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
nifedipine 125491 112715 112499 115823 65.29 0.453
verapamil 24334 22000 21896 22513 65.01 0.405
felodipine 69534 65093 64036 65202 67.46 0.454
amlodipine 270918 251316 249972 254876 66.68 0.494
nicardipine 2796 2510 2511 2593 65.91 0.481
Table 6 Information about the sulphonylurea drugs investigated in this paper. Total is the number of times the drug is
prescribed for the first time in 13 months, age is the average age of the patients who are prescribed the drug for the first time
in 13 months and male proportion is the number of patients that are male divided by the total number of patients who are
prescribed the drug for the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
glibenclamide 11874 10356 10377 10768 65.12 0.540
gliclazide 45824 41626 40537 41612 65.02 0.546
glimepiride 10957 10156 9882 10081 64.20 0.534
glipizide 5315 4856 4614 4731 66.50 0.535
tolbutamide 3113 2758 2793 2894 69.40 0.487
Table 7 Information about the penicillin drugs investigated in this paper. Total is the number of times the drug is prescribed
for the first time in 13 months, age is the average age of the patients who are prescribed the drug for the first time in 13 months
and male proportion is the number of patients that are male divided by the total number of patients who are prescribed the
drug for the first time in 13 months.
Drug Total TPD MUTARA ROR Age male proportion
amoxicillin 2795759 2321098 1593874 1718875 38.84 0.427
benzylpenicillin 2071 1610 1840 1972 31.79 0.471
flucloxacillin 971174 834017 729967 765428 41.42 0.456
phenoxymethly 55397 45941 45679 48142 29.67 0.396
ampicillin 80655 63458 64827 69381 39.18 0.423
The precision of each method at cutoff K, denoted
P (K), is defined as the fraction of known ADRs that
occur in the top K events of the list returned by each
algorithm for a specific drug, see Eq. (14).
P (K) =
∑K
i=1 y(i)
K
(14)
The average precision (AP) is a measure that can
be used to determine how well an algorithm generally
ranks the medical events associated to a drug. This
measure has previously been applied to compare algo-
rithms implemented on a different EHD [19].
The AP is calculated by finding the average P (K)
for each K corresponding to a known ADR,
AP =
∑
K:y(K)=1
P (K)∑
i y(i)
(15)
Using Table 9 as an example, as there are two known
ADRs returned (
∑
i y(i) = 2) and the known ADRs in
the table are ranked second and third we have {K :
y(K) = 1} = {2, 3}, so the AP score is,
AP =
P (2) + P (3)
2
=
1/2 + 2/3
2
=
7
12
(16)
It was also possible to investigate how well each
algorithm ranks the known adverse drug events for a
specific drug depending on how common they are. As
the BNF states the risk of each known ADR by sepa-
rately listing frequently, less frequently and rarely oc-
curring known ADRs we also calculated the AP score
of each algorithm when only considering rarely occur-
ring known ADRs (as unknown ADRs are likely to be
rare). So, we calculate the AP scores for two different
situations; considering all known ADRs and considering
only rarely occurring known ADRs. When considering
only the rare ADRs, the known common and less com-
mon ADRs are filtered from the list of medical events
returned by each algorithm. The reason for filtering the
common and less common known ADRs is to prevent
their presence causing a low AP score when only con-
sidering rare ADRs, as if an algorithm did not filter the
common and less common known ADRs and correctly
ranks these highly (above the rare ADRs) then the rare
ADRs would have a lower rank, which would result in
a lower AP score when only considering rare ADRs.
To give a general measure of the ranking ability of
each algorithm over all the drugs investigated (rather
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Table 9 An example of the medical event list associated to a specific drug and ordered by one of the algorithms.
Medical Event Rank Score Known ADR y(i)
Event 1 2.34 No y(1) = 0
Event 5 2.12 Yes y(2) = 1 precision2 = 1/2
Event 4 1.75 Yes y(3) = 1 precision3 = 2/3
Event 2 1.74 No y(4) = 0
Event 3 0.68 No y(5) = 0
Table 10 An example of the medical event list for all the drugs and ordered by one of the algorithms.
Drug Medical Event Rank Score Known ADR y(i)
Drug 10 Event 7 2.34 No y(1) = 0
Drug 10 Event 5 2.12 Yes y(2) = 1
Drug 2 Event 56 1.75 Yes y(3) = 1
Drug 9 Event 7 1.74 No y(4) = 0
Drug 2 Event 16 0.68 No y(5) = 0
Table 11 The specificity and sensitivity at the natural
thresholds for the different algorithms (3dp).
Algorithm Signals Sens Spec Precision
HUNT60 7785 0.179 0.903 0.0541
HUNT180 7785 0.193 0.903 0.058
MUTARA60 67624 0.933 0.109 0.032
MUTARA180 65435 0.914 0.136 0.032
TPD 1 1893 0.090 0.953 0.057
TPD 2 3557 0.107 0.926 0.043
ROR05 37729 0.312 0.726 0.031
than calculating ranking measures per drug) we also
compute ROC plots. The ROC plots were generated by
combining all the drug results for each algorithm, as il-
lustrated in Table 10 and calculating the sensitivity and
specificity for signals generated at a range of signalling
thresholds. The ROC curves are formed by plotting the
true positive rate (TPR=sensitivity) against the false
positive rate (FPR=(1-specificity)). The Area Under
the Curve (AUC) was approximated using the trape-
zoidal rule for FPR ranging between 0-1, 0-0.3 and 0-0.1
(AUC[0,1],AUC[0,0.3] and AUC[0,0.1] respectively).
4 Results
4.1 Natural Thresholds
Table 11 shows the specificity and sensitivity for the
different algorithms at their natural threshold and the
number of signals generated. The natural threshold for
the ROR and TPD are that their lower confidence in-
terval value is greater than 1 and 0 respectively. MU-
TARA does not have a lower confidence interval calcu-
lation, so the natural threshold implemented is that the
unexpected-leverage is greater than 0 and for HUNT
the top 10% of medical events were signalled.
Table 12 The AUC results for the different algorithms
(3dp).
Algorithm AUC[0,1] AUC[0,0.3] AUC[0,0.1]
HUNT60 0.566 0.072 0.011
HUNT180 0.570 0.071 0.011
MUTARA60 0.596 0.076 0.010
MUTARA180 0.597 0.069 0.010
TPD 1 0.570 0.065 0.009
TPD 2 0.557 0.060 0.007
ROR05 0.546 0.048 0.005
4.2 ROC Analysis
THE AUC[0,1] for the algorithms ranged between 0.546
(ROR05) to 0.597 (MUTARA180), the AUC[0,0.3] for
the algorithms ranged between 0.048 (ROR05) to 0.076
(MUTARA60) and AUC[0,0.1] for the algorithms ranged
between 0.005 (ROR05) to 0.011 (HUNT180 and HUNT60).
Fig. 4 and Fig. 5 show the ROC plots for the different
algorithms.
4.3 AP
Fig. 6 shows the AP scores for the different algorithms
over the range of drugs investigated. The family of drugs
that the algorithms perform worse on overall were the
sulphonylureas with AP scores ranging from 0.0088 −
0.0687. The algorithms all performed well on the cal-
cium channel blockers, with AP scores ranging from
0.0236 − 0.1988, but the ROR05 performed worse for
all the calcium channel blockers investigated. The algo-
rithms also performed well for the tricyclic antidepres-
sants with AP scores ranging between 0.0499− 0.1670.
It can be seen in Fig. 6 that generally the algorithms
perform similarly between the same drugs of the same
class, apart from the algorithms performing much bet-
ter for benzylpenicillin sodium compared to the other
penicillin drugs.
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Fig. 4 The ROC plots for the different algorithms over the whole FPR (1-specificity) range. The black line is the line x=y.
The box plots of the AP scores for the different al-
gorithms seen in Fig. 7 show overall the TPDs, MU-
TARAs and HUNTs perform equally and outperform
the ROR05. The MUTARA algorithm has the highest
median AP score over all the drugs and is more consis-
tent, whereas the performance of the TPD and HUNT
varies more between the drugs. The box plots for the
algorithm AP scores when only considering rare known
ADRs, see Fig. 8, shows that the algorithms AP scores
are lower when ranking rare ADRs, as the maximum
AP score for all the algorithms when only considering
rare known ADRs was less than 0.08, whereas the max-
imum AP scores for all the algorithms when considering
all known ADRs was approximately 0.2.
5 Discussion
5.1 Natural Thresholds
The results show that the natural thresholds operate
at different stringencies. The most stringent algorithm
was the TPD 1 that returned 1893 signals, the lowest
out of all the algorithms, with a high specificity of 0.953
and low sensitivity of 0.09, whereas the less stringent
was the MUTARA60 that returned 67624 signals with
a high sensitivity of 0.933 and a low specificity of 0.109.
This was not unexpected as the TPD threshold used the
lower confidence interval value rather than the actual
IC∆ value and the TPD applied a statistical shrinkage.
The results also show that none of the algorithms was
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Fig. 5 The ROC plots for the different algorithms over the section of FPR (1-specificity) less than 0.3. The black line is the
line x=y.
able to signal the known ADRs without being swamped
by false positives.
5.2 ROC Analysis
The existing EHD algorithms can be implemented to
return a list of medical events in order of how likely
the algorithm has deemed each medical event to be a
potential ADR. In effect, the algorithms act as filters
where lowly ranked medical events are filtered out and
tentative signals are generated for the top n ranked
medical events. These tentative signals are investigated
further with more stringent statistical analysis required
to confirm if they are true signals or not. Therefore, to
discover ADRs, the algorithms need to rank medical
events corresponding to ADRs highly and the higher
they are ranked the more likely they are to be discov-
ered. This shows that AUC[0,0.1] and AUC[0,0.3] give
a direct indication into how likely the algorithms will
detect ADRs. As the natural threshold’s of the algo-
rithms act at different stringencies, the AUC[0,0.1] and
AUC[0,0.3] measures offer a fairer comparison between
the algorithms.
The AUC results show that the algorithm perform
similarly and no algorithm had a higher AUC for all
three FPR cutoff values studied (AUC[0,1],AUC[0,0.3]
and AUC[0,0.1]).
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Fig. 6 Bar chart showing the AP scores for all the drugs, with a dashed line separating the different drug families.
5.3 AP
Overall no algorithm consistently outperformed the oth-
ers over all the drugs investigated in this study, how-
ever, either the TPD 1 or HUNT had the highest AP
score for the majority of the drugs studied. The ROR05
generally performed the worse, but still had a higher
AP score than the other algorithms for the drug phe-
noxymethylpenicillin. As we know the number of times
each drug was prescribed, the average age of the pa-
tients prescribed each drug and the male proportion of
the patients prescribed the drug, we discuss how these
factors impacted on the different algorithms below.
5.3.1 Age
The drugs prescribed to the youngest patients were the
penicillins. The TPD 1 returned the highest AP score
for flucloxacillin, amoxicillin and phenoxymethylpeni-
cillin and HUNT60 returned the highest AP score for
benzylpenicillin sodium and ampicillin. This is consis-
tent with the general results as the TPD 1 and HUNT60
generally had the highest AP score over all the drugs.
Although, compared to the other drugs in the study
all the algorithms performed fairly poorly for the peni-
cillins suggesting drugs that on average are prescribed
to younger patients may require the algorithms to ap-
ply stratification techniques rather than applying the
algorithms to all ages. This is unfortunate as stratifi-
cation is likely to result in an increase in the time it
takes to identify an ADR, as the population of patients
being prescribed a drug needs to be partitioned by age
but there is a lower limit to the patient size required
for the algorithms to work accurately.
The drugs prescribed to the oldest patients were
tolbutamide, felodipine, amlodipine, glipizide and ni-
cardipine with the average age of the patients prescribed
the drugs being 69, 67, 67, 67 and 66 respectively. These
drugs had high AP scores and the TPD performed the
best for all of these drugs. This suggests the TPD is
the optimal algorithm to apply to the THIN database
if the drug is prescribed to older patients. One possi-
ble reason why the TPD is better at ranking ADRs for
older patients may be due to older patients experiencing
more medical events, so there are more medical events
to rank, but as the TPD applies a filter it can remove
many of these medical events, increasing the chance of
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Fig. 7 Box plot showing the median, quartiles and minimum/maximum AP scores for each algorithm applied to all the drugs.
ranking a known ADR highly, whereas the other algo-
rithms apply less stringent filters.
5.3.2 Gender Bias
The drugs with the greatest gender bias towards fe-
males (prescribed more often to females) were the drugs
norfloxacin, lofepramine , nortriptyline and doxepin with
male proportions of 0.26,0.28, 0.29 and 0.32 respec-
tively. Apart from lofepramine, MUTARA and HUNT
perform much better for the drugs prescribed more to
females than males. This may highlight the need for
MUTARA and HUNT to be applied to a subset of the
patients such as old females or young males as was im-
plemented originally for MUTATA and HUNT.
The drugs gliclazide, glibenclamide, glipizide and
glimepiride are prescribed more often to males than fe-
males with a male proportion of 0.55, 0.54, 0.53 and
0.53 respectively. These drugs had the lowest AP scores
compared to all the other drugs investigated and pos-
sibly suggests that the algorithms have difficulties de-
tecting ADRs for drugs prescribed more often to males.
This result is not unexpected as patients taking part
in clinical trails are predominately male, so the known
ADRs for drugs frequently prescribed to males are more
likely to be rare (otherwise they would be discovered
during the clinical trials).
5.3.3 Low Prescription Rates
The drugs that had the lowest number of prescriptions
in the database were fenoprofen, moxifloxacin, benzyl-
penicillin and tolbutamide with only 1255, 1465, 2027
and 3113 prescriptions respectively. These four drugs
had a varied average age of patients prescribed the
drugs and male proportion. Looking at Fig 6 we can
see that the AP scores for these drugs are the best or
second best when comparing against the drugs in the
same family. This result shows that the existing algo-
rithms applied to the THIN database are able to detect
ADRs after around one thousand patients have been
prescribed a drug and may be able to detect ADRs in
new drugs more efficiently that applying existing al-
gorithms to SRS databases. Furthermore, HUNT per-
formed the best for the three drugs with the lowest
number of prescriptions, suggesting HUNT may be the
optimal algorithm to apply when a drug is newly mar-
keted.
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Fig. 8 Box plot showing the median, quartiles and minimum/maximum AP scores for each algorithm when only considering
rare known ADRs for all the drugs.
5.4 Detecting rare ADRs
The results show that none of the existing algorithms
is able to rank rare ADRs highly and currently the ex-
isting algorithms tend to focus on detecting more com-
mon ADRs. A possible reason for this with the TPD
is because it is more stringent as the calculation is bi-
ased to reduce the IC∆ when a medical event is rare,
this means that we can be more confident about signals
generated by the TPD, but at the cost that rarer ADRs
may take longer to be signalled. The reason MUTARA
and HUNT struggle to rank rare ADRs highly is likely
due to non ADR medical events that are linked to the
cause of the drug incorrectly having a high rank and
pushing the rare ADRs down the ranked list.
This is an important result as the currently un-
known ADRs are either likely to be rare or correspond
to medical events with a high background rate, as more
obvious ADRs will be discovered during clinical trails
or by mining SRS databases.
5.5 Discussion of Existing Algorithms
There does not appear to be an optimal reference pe-
riod to apply for HUNT out of Tr = 60 or Tr = 180 as
HUNT180 returned a better AP score that HUNT60 for
some drug and worse for others. This shows the refer-
ence period used by HUNT has a large impact on the
outcome and should be different for each drug. The rea-
son for this is that the reference period should depend
on the background rate of the drugs ADRs, as if the
ADR is common, having a large reference period will
mean that the ADRs is likely to occur during the refer-
ence period and be incorrectly filtered. However, these
is also a downside to having a short reference period as
the shorter the reference period the less likely the al-
gorithm will filter medical events have are repeats. An
improvement to MUTARA and HUNT would be to de-
velop a way to learn the optimal reference period to use
for each drug. MUTARA and HUNT also have issues
due to using a random period of time in the non-user se-
quences making the algorithms non deterministic and in
this paper we did not study how much the results vary
between different implementations of the algorithms.
18 Jenna Reps1 et al.
We investigated the two different filters for the TPD
and interestingly including the day of prescription into
the filter improved the AP scores for the majority of
drugs, this suggests that most ADRs are not recorded
on the same day as the drug is prescribed. However,
for some drugs the TPD 2 outperformed the TPD 1, so
using the day of prescription in the filter does occasion-
ally prevent the detection of known ADRs. In summary,
including the day of prescription into the filter for the
TPD generally increases the algorithms precision but
at a cost as it can prevent the detection of some ADRs.
5.6 Previous Work and Limitations
The results obtained in this study were consistent with
previous results as the P (10) for MUTARA and HUNT
averaged 0.065 and 0.122 respectively in this study and
were 0.1 and 0.1 − 0.3 respectively in previous work
[11][12]. The P (10) for the TPD method applied to
Nifedipine in this study was 0.7, the same as on the UK
IMS Disease Analyzer database [15]. However, there
was deviation between the AP score of the ROR05 in
this study (0.01 − 0.06) and in the study by Zorych et
al. [28] (0.1-0.15), this is probably due to this study us-
ing real data with redundant Read codes and Zorych et
al. using simulated data.
One limitation with this study is that there is no
‘gold standard’ for ADR detection and it is impossi-
ble to calculate the true sensitivity, specificity and AP
scores of the algorithms as the complete set of ADRs
for each drug is unknown and the algorithms may cor-
rectly rank an unknown ADR highly but this would
lower the sensitivity, specificity and AP values in this
study due to the event not being listed by the BNF as
a known ADR. However, the algorithms should be able
to correctly rank the known ADRs and these are likely
to be more common and obvious, so if the algorithm is
unable to correctly rank these above noise events then
it is unlikely to identify the unknown ADRs, so the AP
scores determined in this study still give insight into the
algorithms abilities to detect ADRs. The redundancy
in the Read Codes may also result in biased results as
similar medical events with different Read Codes may
get ranked closely and push down the ranks of known
ADR, so the algorithms may have higher AP scores if
there was a way to group Read Codes corresponding to
the same medical event.
6 Conclusions
In this paper we compared four existing ADR detect-
ing algorithms by applying them to the THIN data-
base for a range of drugs and measured how well they
ranked the known ADRs or signal known ADRs at their
natural thresholds. We have determine that the bench-
mark AP score for ADRs signalling algorithms applied
to the THIN database is 0.2, the benchmark AUC[0,0.1]
is 0.011 (3dp) and AUC[0,0.3] is 0.076 (3dp). Future al-
gorithms should aim for higher scores. The results show
that no algorithm was superior for all the drugs consid-
ered, although the results do indicate that HUNT may
be the optimal algorithm to apply when the number
of patients prescribed the drug is low or the TPD may
be optimal when the patients are old, however further
research needs to be conducted to confirm these hy-
potheses. However, in many situations at present, the
tentative ADR signals should be generated based on
how the medical events are ranked by all the different
algorithms rather than relying on one algorithm alone.
The results also clearly show that the existing algo-
rithms are not capable of detecting rare ADRs, but one
of the potential advantages of mining the THIN data-
base compared with mining the SRS databases it the
ability to detect rare ADRs that are under-reported in
SRS databases. For example, some rare but fatal ADRs
might never be noticed and reported into an SRS data-
base and would therefore be undetectable by mining
SRS databases.
Future work could focus on developing new filters
that are able to remove the medical events that are re-
lated to the cause of taking the drug but do not occur
before the drug is prescribed, such as illness progression
events. This would then reduce the number of false pos-
itive associations that are returned by the algorithms.
Future work should also address the limitations of this
study by developing a way to cluster the Read codes
and reduce their redundancy.
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